Alkermes Survey Explores Impact of Bipolar I Disorder Medication Side Effects

Mar 2, 2022 12:05 PM ET

Originally published on LinkedIn

Our recent survey conducted with Harris Poll and Depression and Bipolar Support Alliance found that a vast majority of respondents who live with bipolar I disorder experienced medication side effects that negatively impacted their daily lives.

Learn more.

About Alkermes
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at